Tuesday, Nov 18 — Shares of Emcure Pharmaceuticals Ltd opened lower in early trade, quoting Rs 1,341, down 2.25%, as global investment firm BC Investments (Bain Capital) is likely to sell up to 2% of the company’s total equity through a block deal. The indicative floor price has been set at Rs 1,296.51 per share.
The floor price reflects a discount of nearly 7% to Emcure’s Rs 1,394.10 closing price on the NSE on November 17, 2025. The block deal size is estimated at up to Rs 493 crore. Shares sold through the block deal will carry a 90-day lock-in before any subsequent sale. As of Q2 2025, BC Asia held a 6.3% stake in the company.
Q2 Financial Performance
Emcure Pharmaceuticals reported a 25.1% year-on-year increase in consolidated net profit to Rs 243 crore for the September 2025 quarter, compared with Rs 194 crore in the same period last year. Revenue from operations rose 13.4% to Rs 2,269.8 crore, up from Rs 2,001.9 crore in Q2 FY25.
EBITDA increased 25% to Rs 475.4 crore, compared with Rs 380.3 crore a year ago, while EBITDA margin improved to 21% from 19%, supported by a favourable product mix and cost efficiencies.
The company said its operational performance reflected strong momentum across domestic and international markets. Emcure continues to maintain a diversified presence across gynaecology, cardiovascular therapies, HIV antivirals, pain management, and emerging markets.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
